27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Shockwave Medical Inc's (NASDAQ:SWAV) second-quarter FY21 sales were up 4-fold to $55.9 million beating the Wall Street consensus of $45.17 million.
- The growth was primarily driven by the launch of the coronary product, Shockwave C2, in the U.S. in February and the increased adoption of Shockwave products.
- Gross margin improved to 82% from 65% due to the launch of Shockwave C2 and continued improvements in manufacturing productivity and process efficiencies.
- Cash, cash equivalents, and short-term investments totaled $174.7 million.
- The company posted a Q1 EPS loss of ($0.01), much narrower than the loss of $(0.56) a year ago and surpassing the analyst consensus estimate of ($0.41) loss.
- Guidance: Shockwave Medical raised FY21 sales outlook of $218 million - 223 million (consensus of $200.64 million), higher than previous guidance of $195 million - $205 million.
- Price Action: SWAV shares are up 4.21% at $190.55 during the market session on the last check Monday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!